Are restricted mean survival time methods especially useful for noninferiority trials?
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Are restricted mean survival time methods especially useful for noninferiority trials?
Authors
Keywords
-
Journal
Clinical Trials
Volume -, Issue -, Pages 174077452097657
Publisher
SAGE Publications
Online
2021-02-25
DOI
10.1177/1740774520976576
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- On the empirical choice of the time window for restricted mean survival time
- (2020) Lu Tian et al. BIOMETRICS
- Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations
- (2020) Anne Eaton et al. Clinical Trials
- Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes
- (2020) David E. Kloecker et al. ANNALS OF INTERNAL MEDICINE
- Is the Log-Rank and Hazard Ratio Test/Estimation the Best Approach for Primary Analysis for All Trials?
- (2020) Hajime Uno et al. JOURNAL OF CLINICAL ONCOLOGY
- Estimating Treatment Effect as the Primary Analysis in a Comparative Study: Moving Beyond P Value
- (2020) Bo Huang et al. JOURNAL OF CLINICAL ONCOLOGY
- Reply to H. Uno et al and B. Huang et al
- (2020) Boris Freidlin et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of survival distributions in clinical trials: A practical guidance
- (2020) Xiaotian Chen et al. Clinical Trials
- Biodegradable-polymer stents versus durable-polymer stents
- (2019) Lee-Jen Wei et al. LANCET
- Restricted mean survival time for the analysis of cardiovascular outcome trials assessing non-inferiority: Case studies from antihyperglycemic drug development
- (2019) David H. Manner et al. AMERICAN HEART JOURNAL
- Using the Restricted Mean Survival Time Difference as an Alternative to the Hazard Ratio for Analyzing Clinical Cardiovascular Studies
- (2019) Zachary R. McCaw et al. CIRCULATION
- Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?
- (2019) Boris Freidlin et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
- (2018) Joseph A. Sparano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Design of non-inferiority randomized trials using the difference in restricted mean survival times
- (2018) Isabelle R Weir et al. Clinical Trials
- Demonstrating Noninferiority of Accelerated Radiotherapy With Panitumumab vs Standard Radiotherapy With Cisplatin in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma
- (2017) David Cheng et al. JAMA Oncology
- Restricted Mean Survival Time as a Measure to Interpret Clinical Trial Results
- (2017) Dae Hyun Kim et al. JAMA Cardiology
- Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials
- (2016) Ludovic Trinquart et al. JOURNAL OF CLINICAL ONCOLOGY
- Statistical issues in the analysis of adverse events in time-to-event data
- (2016) Arthur Allignol et al. PHARMACEUTICAL STATISTICS
- Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies
- (2015) Hajime Uno et al. ANNALS OF INTERNAL MEDICINE
- Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome
- (2013) Patrick Royston et al. BMC Medical Research Methodology
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started